Marinus Pharmaceuticals Shares Mixed Results From IV Formulated Ganaxolone In Pretreated Seizure Patients
Portfolio Pulse from Vandana Singh
Marinus Pharmaceuticals announced mixed results from its Phase 3 RAISE trial for IV ganaxolone in treating refractory status epilepticus (RSE). While the drug showed significant efficacy in stopping status epilepticus within 30 minutes, it failed to achieve statistical significance in preventing progression to IV anesthesia. The company plans to continue analyzing the data and engage with the FDA for further steps.
June 17, 2024 | 1:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Marinus Pharmaceuticals' Phase 3 RAISE trial for IV ganaxolone showed mixed results. The drug was effective in stopping status epilepticus within 30 minutes but failed to prevent progression to IV anesthesia. The stock is down 7.52% in premarket trading.
The mixed results from the Phase 3 RAISE trial have led to a negative market reaction, with the stock down 7.52% in premarket trading. The efficacy in stopping status epilepticus is a positive, but the failure to prevent progression to IV anesthesia is a significant drawback.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100